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Abstract  Since  its  ﬁrst  description  by  Denis  Burkitt,  endemic  Burkitt’s  lymphoma  (BL),  the
most common  childhood  cancer  in  sub-Saharan  Africa,  has  led  scientists  to  search  for  clues  to
the origins  of  this  malignancy.  The  discovery  of  Epstein-Barr  virus  (EBV)  in  BL  cells  over  50  years
ago led  to  extensive  sero-epidemiology  studies  and  revealed  that  rather  than  being  a  virus
restricted  to  areas  where  BL  is  endemic,  EBV  is  ubiquitous  in  the  world’s  population  with  an
estimated greater  than  90%  of  adults  worldwide  infected.  A  second  pathogen,  Plasmodium  fal-
ciparum (P.  falciparum)  malaria  is  also  linked  to  BL.  In  this  review,  we  will  discuss  recent  studies
that indicate  a  role  for  P.  falciparum  malaria  in  dysregulating  EBV  infection,  and  increasing  the
risk for  BL  in  children  living  where  P.  falciparum  malaria  transmission  is  high.
© 2016  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Hospital  Infantil  de  Méx-
ico Federico  Gómez.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infección  en  lactantes  por  virus  de  Epstein-Barr:  implicaciones  de  la  infección
a  temprana  edad  sobre  el  control  viral  y  el  riesgo  de  linfoma  de  Burkitt
Resumen  Desde  la  primera  descripción  por  Denis  Burkitt,  el  linfoma  de  Burkitt  (LB)  endémicofalciparum;
Malaria;
Citidina  desaminasa
inducida  por
----el tipo  de  cáncer  pediátrico  más  común  en  el  África  subsahariana----  ha  guiado  a  los  cientí-
ﬁcos a  investigar  este  padecimiento  en  la  búsqueda  de  claves  para  entender  sus  orígenes.  El
descubrimiento  desde  hace  50  an˜os  del  virus  de  Epstein-Barr  (VEB)  en  el  LB  ha  conducido  a
extensos estudios  sero-epidemiológicos  y  ha  revelado  que,  más  que  ser  un  virus  restringido  a
áreas donde  el  LB  es  endémico,  el  VEB  es  ubicuo  en  la  población  mundial,  con  un  estimado
 infectados  a  escala  global.  Un  segundo  agente  patógeno  se  ha
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ligado  al  LB,  el  Plasmodium  falciparum  (P.  falciparum)  malaria.  En  esta  revisión  se  discuten
los estudios  recientes  que  indican  el  papel  de  P.  falciparum  malaria  en  la  desregulación  de  la
infección  por  VEB  y  en  el  aumento  del  riego  del  LB  en  nin˜os  que  viven  en  regiones  con  alta
transmisión  de  P.  falciparum  malaria.
© 2016  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Hospital  Infantil  de
México Federico  Gómez.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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s. Introduction
urkitt’s  lymphoma  (BL)  is  a  monoclonal  B  cell  non-Hodgkin’s
ymphoma  with  a  high  proliferative  index1.  Endemic  BL  is
xtranodal  and  tumors  are  frequently  found  in  the  jaw
r  abdominal  region2.  The  peak  age  of  onset  is  6  years3
ndicating  that  there  is  a  very  short  time  frame  between
xposure  to  cancer  promoting  events  and  the  emergence  of
alignancy.  There  are  three  forms  of  BL  found  worldwide:
ndemic,  sporadic,  and  AIDS-associated  and  all  carry  a  t8;14
hromosomal  translocation  resulting  in  the  deregulation  of
he  c-myc  oncogene4,5.  It  is  likely  however,  that  different
athogenic  mechanisms  drive  the  emergence  of  these  BL
ubtypes6,7.  The  focus  of  this  review  is  on  the  endemic  form
f  BL  (herein  referred  to  simply  as  BL).
Both  molecular  and  epidemiologic  studies  have  indicated
hat  there  is  an  etiologic  link  between  EBV  and  the  endemic
orm  of  BL8--11.  At  the  molecular  level,  the  viral  genome  is
resent  in  all  cells12,  exists  as  a  clonal  population  within
he  tumors9 and  the  viral  protein  EBNA-113 along  with  viral
on-coding  BART  microRNAs14,15 are  consistently  expressed
ithin  the  tumors.  In  addition,  the  capacity  of  EBV  to  trans-
orm  B  cells  also  highlights  the  virus’  oncogenic  potential.
 large-scale  prospective  study  conducted  in  Uganda  in  the
970s  provided  evidence  that  EBV  infection  was  a  risk  factor
or  BL.  In  this  study,  greater  than  40,000  children  were  pre-
led,  serum  was  stored  and  when  tumors  appeared,  very
igh  antibody  titers  against  the  EBV  viral  capsid  antigen
VCA)  were  found  in  children  who  subsequently  developed
L.  The  elevated  VCA  titers,  and  the  stability  of  the  ele-
ated  VCA  antibodies  over  time,  led  de-Thé  et  al.16 to
uggest  that  infection  of  infants  with  EBV  early  in  life  could
esult  in  an  infection  that  was  poorly  controlled  by  the  host
nd  thus  increased  the  risk  for  BL.  Plasmodium  falciparum,
s  also  connected  to  BL  both  based  on  the  overlapping
egions  of  high  malaria  transmission  with  areas  of  high  BL
ncidence17--20 as  well  as  case  control  studies21,22.
. Epstein-Barr virus transmission
BV  is  an  enveloped  gamma  herpes  virus  that  is  transmit-
ed  primarily  through  contact  with  saliva23.  In  developed
ountries,  there  is  a  biomodal  distribution  of  the  age  of  EBV
nfection  with  30-50%  of  children  infected  before  5  years  of
ge  and  then  a  later  transmission  occurring  in  young  adult-
ood.  For  example,  in  a  recent  study  by  Condon  et  al.,  they
valuated  the  seroprevalence  of  EBV  infection  in  a  cross-
ectional  study  of  children  in  the  U.S.  aged  18  months-
0  years  of  age.  They  found  that  31%  of  the  children
ere  EBV  seropositive  by  5  years  of  age,  whereas  71%  were
i
o
t
eeropositive  by  19  years  of  age24.  Infection  in  childhood  is
hought  to  be  primarily  asymptomatic  while  the  later  age
f  infection  can  cause  infectious  mononucleosis  (IM),  a  self-
imiting  disease25.  IM  is  characterized  by  expansion  of  both
BV-speciﬁc  and  non-speciﬁc  CD8+  T  cells.  In  a  study  of  Gam-
ian  infants  infected  with  EBV  by  14  months  of  age,  although
here  was  EBV-speciﬁc  CD8  T  cells  detected,  there  was  no
oncurrent  over  expansion  of  the  CD8+  T  cell  pool26 perhaps
xplaining  why  EBV  infection  in  infants  is  asymptomatic.
There  are  a  limited  number  of  published  longitudinal
tudies  on  primary  EBV  infection  in  infants27--32 and  most
ave  utilized  only  serologic  markers  as  indicators  of  infec-
ion.  In  a  more  recent  study  following  an  infant  cohort
orn  in  rural  areas  in  Kenya,  signiﬁcantly  higher  levels  of
BV  infection  at  less  than  1  year  of  age  were  observed
s  compared  to  other  studies31.  Of  note,  in  the  malaria
igh  transmission  area,  35%  of  infants  were  infected  with
BV  by  6  months  of  age  suggesting  that  malaria  infection
odulated  the  age  of  EBV  infection31.  Early  age  of  EBV
nfection  was  also  observed  in  Kenyan  infants  born  to  HIV
nfected  mothers32.  Both  of  these  studies  found  that  early
ge  of  acquisition  of  EBV  was  associated  with  a  poor  control
f  EBV  infection  as  indicated  by  high  viral  loads  that  were
aintained  over  time.  The  neonatal  immune  system  is  not
s  effective  as  the  adult  immune  system  for  reasons  that
nclude  lack  of  immunologic  memory,  immaturity  and  ske-
ing  towards  a  Th2  phenotype33--35.  Early  transmission  of  EBV
ould  induce  tolerance  of  the  viral  antigen  and  consequently
imit  the  speciﬁc  immune  response,  as  seen  for  early  age
f  hepatitis  B  virus  infection36. Alternatively,  infants  lack  a
ully  functional  cytotoxic  T  cell  response  before  12  months
f  age34, so  infection  early  in  life  could  lead  to  ineffec-
ive  or  minimal  control  of  the  virus.  Early  age  of  infection
ith  subsequent  high  viral  loads  could  increase  the  risk  for
ubsequent  EBV-associated  malignancies.
An  alternative  source  of  EBV  transmission  has  been
ypothesized  to  be  breast  milk37--39 but  in  most  studies  to
ate,  only  viral  DNA  was  measured.  More  recently,  infec-
ious  virus,  not  just  viral  DNA,  was  found  in  breast  milk
roviding  support  to  the  hypothesis  that  breast  milk  could
e  a  source  for  EBV  transmission40. Pregnant  women  with
alaria  have  high  viral  loads41,  and  the  loss  of  control  of
BV  latency  following  P.  falciparum  infection  during  preg-
ancy  and  subsequent  increase  in  EBV  load  in  circulation
ossibly  contribute  to  enhanced  shedding  of  EBV  in  maternal
reast  milk  post-partum40 and  drives  early  age  of  transmis-
ion  of  EBV.  EBV  DNA  was  detected  in  breast  milk  of  HIV
nfected  mothers38,39 and  this  could  contribute  to  early  age
f  EBV  infection  in  infants  born  to  HIV  infected  women.  Why
here  is  higher  prevalence  of  EBV  in  breast  milk  of  moth-
rs  in  developing40 as  compared  to  developed  countries42
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could  also  reﬂect  the  higher  burden  of  EBV  in  the  general
population.
3. EBV persistence
A  model  for  EBV  persistence  proposed  by  Thorley-Lawson,
the  Germinal  Center  (GC)  Model,  is  an  elegant  model  based
on  years  of  study  of  healthy  U.S.  adults43.  In  this  model,
EBV  exploits  the  differentiation  of  B  cells  in  the  lymphoid
tissue  to  set  up  a  lifelong  persistent  latent  infection  in
memory  B  cells  in  equilibrium  with  the  host.  In  healthy,
EBV-seropositive  adults,  there  is  a  stable,  low  frequency  of
latently  infected  cells  estimated  at  1-200  EBV  positive  B  cells
in  105 total  B  cells44.  Without  enrichment  for  B  cells  from
peripheral  blood,  it  is  difﬁcult  to  detect  EBV  infected  cells
in  healthy  EBV  seropositive  adults  by  PCR  ampliﬁcation  using
real-time  quantitative  PCR45,46 or  quantitative  competitive
PCR47.  However,  unaccounted  for  in  this  model  is  how  other
systemic  infections  can  inﬂuence  EBV  persistence.
3.1.  Malaria  and  EBV  persistence
In  the  last  decade,  several  studies  have  pointed  to  a  pro-
found  dysregulation  of  EBV  persistence  and  immunity  in
children  due  to  malaria31,46,48--57.  Repeated  malaria  infec-
tions  during  infancy  expand  the  viral  load54 and  an  expansion
of  EBV  infected  cells  during  acute  malaria  has  also  been
found49,58.  The  cysteine  rich  interdomain  1  (CIDR1) of
the  P.  falciparum  erythrocyte  membrane  protein,  which  is
expressed  in  infected  red  blood  cells,  binds  to  non-immune
immunoglobulins,  and  acts  as  a  T-cell  independent  B-cell
activator59 and  induces  EBV  reactivation  from  B  cells60. EBV
is  more  frequently  reactivated  in  children  living  in  a  malaria
endemic  region48 and  more  directly,  elevated  viral  DNA  in
plasma  is  found  during  acute  malaria51,52.  A  decline  in  EBV
DNA  in  the  plasma  following  anti-malaria  treatment53 is  also
indicative  of  viral  reactivation  driven  by  Plasmodium  infec-
tion.
In  children  living  in  a  malaria  endemic  region,  EBV  viral
loads  are  more  readily  detected  as  compared  to  west-
ern  controls46,49 suggestive  of  a  long-term  consequence  of
repeated  malaria  infections.  More  recently,  in  regions  of
the  Gambia  where  malaria  transmission  has  been  reduced,
the  dysregulation  of  EBV  immunity  by  malaria  appears  to
have  also  been  minimized61.
4. Activation induced cytidine deaminase
(AID) and BL
While  it  is  likely  that  elevated  EBV  load  increases  the  risk  for
BL,  the  mechanistic  link  is  unknown.  In  transplant  patients,
EBV  viral  load  is  monitored  closely  and  elevated  viral  load  is
associated  with  increased  risk  for  post-transplant  lympho-
proliferative  disease62 yet  these  patients  do  not  go  on  to
develop  BL.  So,  elevated  viral  load  alone  is  not  sufﬁcient  for
the  emergence  of  a  malignant  clone.  Recent  clues  point  to
a  model  where  chronic  antigenic  activation  of  EBV-infected
B  cells  within  the  context  of  repeated  P.  falciparum  infec-
tions  may  lead  to  cytogenetic  abnormalities  induced  by  the
enzyme  activation  induced  cytidine  deaminase  (AID)63--65.
o
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AID  is  required  for  class  switch  recombination  and
omatic  hypermutation  in  germinal  center  B  cells66.  But
ID  over-expression  in  AID  deﬁcient  B  cells  was  sufﬁcient
o  induce  IgH-c-myc  translocations67 characteristic  of  BL.
ID  also  induces  lesions  on  the  c-myc  gene68.  In  addi-
ion,  when  E-c-myc  transgenic  mice  were  crossed  with
ID  deﬁcient  mice,  only  AID+/+  mice  developed  predomi-
antly  mature  B  cell  lymphomas69.  The  strongest  evidence
or  a  role  of  aberrant  AID  activation  by  Plasmodium  infec-
ion  comes  from  a  recent  study  by  Robbiani  et  al.70 In
his  study,  the  authors  found  that  repeated  infections  of
53-deﬁcient  mice  with  Plasmodium  chabaudi  resulted  in
evelopment  of  B-cell  lymphomas  that  had  the  character-
stic  c-myc  translocation.  Moreover,  development  of  the
ymphomas  was  dependent  on  AID.  Although  these  studies
ere  done  in  mouse  models,  these  data  argue  for  a critical
ole  of  AID  in  the  c-myc:IgH  translocation  characteristic  of
L  and  suggest  that  aberrant  AID  expression  could  be  a  risk
actor  for  lymphomagenesis.  In  support  of  this  hypothesis,
 strong  correlation  between  AID  expression  in  peripheral
lood  lymphocytes  and  increased  risk  for  non-Hodgkin’s  lym-
homa  was  observed71,72 and  children  who  were  EBV  viral
oad  positive  from  a  malaria  endemic  region  were  found  to
ave  elevated  AID  expression63. Cell  culture  studies  showed
hat  P.  falciparum  could  induce  AID  activation  and  class
witch  recombination  in  B  cells64,73.  If  overexpression  of
-myc  occurred  following  an  AID-mediated  translocation,
ormal  B  cells  would  die  by  apoptosis.  However,  EBV  latent
roteins  are  anti-apoptotic  and  could  thus  allow  a  B  cell  to
olerate  the  c-myc  translocation74.
.  BL and EBV association
lthough  EBV  can  be  readily  detected  in  the  endemic  pedi-
tric  form  of  BL  found  in  sub-Saharan  Africa,  there  is  a
ariable  association  of  EBV  with  the  sporadic  form  of  BL.
poradic  BL  that  occurs  in  adults  in  developed  countries
arely  has  EBV  detected  in  the  tumor.  However,  in  South
merica,  there  is  an  intermediate  level  of  EBV  detected
n  sporadic  BL  tumors75. A  larger  series  of  cases  of  BL
rom  Brazil  found  a predominance  of  EBV  detection  in  the
ediatric  form  of  BL  as  compared  to  adults  and  a  higher
revalence  of  pediatric  EBV+  BL  in  the  northern  part  of
razil  where  there  is  also  a  higher  prevalence  of  malaria  and
ther  infectious  diseases76.  The  intermediate  incidence  of
BV  association  with  sporadic  BL  in  South  America  raises  the
uestion  of  whether  malaria  infection  in  other  parts  of  the
orld  outside  sub-Saharan  Africa  could  also  drive  lymphoma-
enesis.  A  key  difference  of  malaria  transmission  in  Africa
s  the  perennial  and  intense  nature  vs.  the  epidemic  and
easonal  transmission  found  in  South  and  Central  America.
owever,  it  is  possible  that  there  could  exist  a  concurrence
f  early  age  of  EBV  infection  and  malaria  infection  that
ould  increase  the  risk  for  lymphomagenesis  in  other  parts
f  the  world.  Studies  on  the  age  of  EBV  infection  in  Latin
merica  remain  few.  A  recent  report  from  a  pediatric  hos-
ital  case  series  in  Mexico  found  symptomatic  EBV  infection
ccurring  in  children  characteristic  of  infectious  mononu-
leosis  with  a  mean  age  of  5  years,77 much  younger  than
een  in  U.S.-based  series23. However,  a  limitation  of  the  Mex-
co  study  is  that  it  was  based  on  hospitalized  cases  rather
44  R.  Rochford
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Figure  1  Model  for  interaction  between  EBV  and  P.  falciparum  malaria.  P.  falciparum  (Pf)  malaria  results  in  EBV  transmission
in infants  <6  months  of  age.  These  infants  have  poor  control  of  EBV  infection  and  a  higher  number  of  latently  infected  cells.
Repeated infection  with  P.  falciparum  throughout  infancy  and  early  childhood  expands  the  number  of  infected  cells  by  inducing  EBV
reactivation and  reinfection  of  new  pool  of  B  cells  as  well  as  suppression  of  EBV  T  cell  immunity.  P.  falciparum  can  also  act  on  the
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RBV infected  B  cells  to  induce  AID  via  TLR9  ligation  and  subseq
n the  infected  B  cells,  the  c-myc  translocation  is  tolerated  and
han  a  population-based  study  so  true  incidence  cannot  be
etermined.  Nonetheless,  this  study  does  suggest  that  EBV
nfection  is  occurring  in  very  young  children  in  Mexico.
ummary
umulative  evidence  suggests  that  EBV  persistence  is  in
ysequilibrium  when  primary  infection  occurs  in  very  young
nfants  and  co-infection  with  P.  falciparum  malaria  is
ommon.  The  prevailing  model  for  EBV  persistence,  the
erminal  center  model,  was  based  on  studies  of  healthy
.S.  adults  and  as  such  does  not  take  into  account  the
isruption  to  B cell  homeostasis78,79 and  germinal  center
rchitecture  that  occurs  during  acute  P.  falciparum  malaria
nfection80 or  the  ability  of  Plasmodium  to  directly  inter-
ct  with  B  cells  through  either  TLR9  ligation81 or  binding  of
he  P.  falciparum-infected  red  blood  cell  to  B  cells60. This
ysequilibrium  of  EBV  persistence  results  in  high  numbers  of
atently  infected  cells,  which  are  at  risk  for  AID  activation
nduced  by  P.  falciparum  and  subsequent  c-myc  transloca-
ion  (Fig.  1).  Not  discussed  in  this  review  is  a  potential  role
or  EBV  to  suppress  apoptotic  pathways  in  latently  infected
ells,82 which  would  allow  B  cells  with  a  c-myc  translocation
o  emerge.  It  remains  to  be  seen  whether  other  pathogens
an  also  lead  to  dysequilibrium  of  EBV  infection  and  higher
iral  loads  and  account  for  some  of  the  diverse  burden  of
BV-associated  malignancies  worldwide.onﬂict of interest
he  author  declares  no  conﬂict  of  interest  of  any  nature.
1 c-myc  translocation.  Because  EBV  induces  epigenetic  changes
re  is  emergence  of  a  malignant  B  cells.
eferences
1. Magrath IT. African Burkitt’s lymphoma. History, biology, clin-
ical features, and treatment. Am J Pediatr Hematol Oncol.
1991;13:222--46.
2. Mwanda OW. Clinical characteristics of Burkitt’s lymphoma
seen in Kenyan patients. East Afr Med J. 2004; Suppl 8:
S78--89.
3. Mwanda OW, Rochford R, Moormann AM, Macneil A, Whalen C,
Wilson ML. Burkitt’s lymphoma in Kenya: geographical, age,
gender and ethnic distribution. East Afr Med J. 2004; Suppl
8:S68--77.
4. Magrath I. The pathogenesis of Burkitt’s lymphoma. Adv Cancer
Res. 1990;55:133--270.
5. Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L.
Burkitt’s lymphoma: new insights into molecular pathogenesis.
J Clin Pathol. 2003;56:188--92.
6. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis
A, et al. Gene-expression analysis identiﬁes novel RBL2/p130
target genes in endemic Burkitt lymphoma cell lines and primary
tumors. Blood. 2007;110:1301--7.
7. Grifﬁn BE, Rochford R. Endemic Burkitt’s lymphoma. In: Robert-
son E, editor. Epstein-Barr Virus. Philadelphia: Caister Academic
Press; 2005.
8. Labrecque LG, Lampert I, Kazembe P, Philips J, Grifﬁn BE. Corre-
lation between cytopathological results and in situ hybridisation
on needle aspiration biopsies of suspected African Burkitt’s lym-
phomas. Int J Cancer. 1994;59:591--6.
9. Neri A, Barriga F, Inghirami G, Knowles DM, Neeguaye J,
Magrath IT, et al. Epstein-Barr virus infection precedes
clonal expansion in Burkitt’s and acquired immunodeﬁciency
syndrome-associated lymphoma. Blood. 1991;77:1092--5.
0. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley
PM, editors. Fields Virology. Philadelphia: Lippincott Williams
and Wilkins; 2001. p. 2575--627.
33
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4Epstein-Barr  virus  infection  of  infants  
11. de-Thé G, Geser A, Day NE, Tukei PM, Williams EH, Beri
DP, et al. Epidemiological evidence for causal relationship
between Epstein-Barr virus and Burkitt’s lymphoma from Ugan-
dan prospective study. Nature. 1978;274:756--61.
12. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W,
Henle G, Clifford P, et al. EBV DNA in biopsies of Burkitt
tumours and anaplastic carcinomas of the nasopharynx. Nature.
1970;228:1056--8.
13. Lindahl T, Klein G, Reedman BM, Johansson B, Singh S.
Relationship between Epstein-Barr virus (EBV) DNA and the
EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma
biopsies and other lymphoproliferative malignancies. Int J Can-
cer. 1974;13:764--72.
14. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF.
Epstein-Barr virus (EBV) in endemic Burkitt’s lymphoma: molec-
ular analysis of primary tumor tissue. Blood. 1998;91:1373--81.
15. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe
P, et al. Promiscuous expression of Epstein-Barr virus genes in
Burkitt’s lymphoma from the central African country Malawi.
Int J Cancer. 2002;99:635--43.
16. de-The G. Is Burkitt’s lymphoma related to perinatal infection
by Epstein-Barr virus. Lancet. 1977;1:335--8.
17. Dalldorf G. Lymphomas of African children with different forms
or environmental inﬂuences. JAMA. 1962;181:1026--8.
18. Morrow RH. Epidemiological evidence for the role of falciparum
malaria in the pathogenesis of Burkitt’s lymphoma. In: Lenoir G,
O’Connor G, Olweny C, editors. Burkitt’s Lymphoma: a Human
Cancer Model. Lyons: IARC Press; 1985. p. 177--85.
19. Facer CA, Playfair JH. Malaria, Epstein-Barr virus, and the gen-
esis of lymphomas. Adv Cancer Res. 1989;53:33--72.
20. Rainey JJ, Mwanda WO, Wairiumu P, Moormann AM, Wilson
ML, Rochford R. Spatial distribution of Burkitt’s lymphoma in
Kenya and association with malaria risk. Trop Med Int Health.
2007;12:936--43.
21. Carpenter LM, Newton R, Casabonne D, Ziegler J, Mbulaiteye
S, Mbidde E, et al. Antibodies against malaria and Epstein-Barr
virus in childhood Burkitt lymphoma: a case-control study in
Uganda. Int J Cancer. 2008;122:1319--23.
22. Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkan-
dawire N, et al. Associations between Burkitt lymphoma among
children in Malawi and infection with HIV, EBV and malaria:
results from a case-control study. PLoS One. 2008;3:e2505.
23. Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed
JA, Knight JA, et al. Behavioral, virologic, and immunologic
factors associated with acquisition and severity of primary
Epstein-Barr virus infection in university students. J Infect Dis.
2013;207:80--8.
24. Condon LM, Cederberg LE, Rabinovitch MD, Liebo RV, Go JC,
Delaney AS, et al. Age-speciﬁc prevalence of Epstein-Barr virus
infection among Minnesota children: effects of race/ethnicity
and family environment. Clin Infect Dis. 2014;59:501--8.
25. Balfour HH Jr, Dunmire SK, Hogquist KA. Infectious mononucle-
osis. Clin Transl Immunol. 2015;4:e33.
26. Jayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell
AI, et al. Early virological and immunological events in asymp-
tomatic Epstein-Barr virus infection in African children. PLoS
Pathog. 2015;11:e1004746.
27. Chan KH, Tam JS, Peiris JS, Seto WH, Ng MH. Epstein-Barr virus
(EBV) infection in infancy. J Clin Virol. 2001;21:57--62.
28. Huang LM, Lee CY, Chang MH, Wang JD, Hsu CY. Primary
infections of Epstein-Barr virus, cytomegalovirus, and human
herpesvirus-6. Arch Dis Child. 1993;68:408--11.
29. Biggar RJ, Henle W, Fleisher G, Böcker J, Lennette ET, Henle
G. Primary Epstein-Barr virus infections in African infants. I.
Decline of maternal antibodies and time of infection. Int J Can-
cer. 1978;22:239--43.
30. Jenson H, McIntosh K, Pitt J, Husak S, Tan M, Bryson Y,
et al. Natural history of primary Epstein-Barr virus infection in45
children of mothers infected with human immunodeﬁciency
virus type 1. J Infect Dis. 1999;179:1395--404.
1. Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moor-
man  AM, et al. Early age at time of primary Epstein-Barr virus
infection results in poorly controlled viral infection in infants
from Western Kenya: clues to the etiology of endemic Burkitt
lymphoma. J Infect Dis. 2012;205:906--13.
2. Slyker JA, Casper C, Tapia K, Richardson B, Bunts L, Huang ML,
et al. Clinical and virologic manifestations of primary Epstein-
Barr virus (EBV) infection in Kenyan infants born to HIV-infected
women. J Infect Dis. 2013;207:1798--806.
3. Morein B, Blomqvist G, Hu K. Immune responsiveness in the
neonatal period. J Comp Pathol. 2007;137 Suppl 1:S27--31.
4. Siegrist CA. The challenges of vaccine responses in early life:
selected examples. J Comp Pathol. 2007;137 Suppl 1:S4--9.
5. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immu-
nity comes of age. Nat Rev Immunol. 2004;4:553--64.
6. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal
Med. 2007;12:160--7.
7. Junker AK, Thomas EE, Radcliffe A, Forsyth RB, Davidson AG,
Rymo L. Epstein-Barr virus shedding in breast milk. Am J Med
Sci. 1991;302:220--3.
8. Viljoen J, Tuaillon E, Nagot N, Danaviah S, Peries M, Paday-
achee P, et al. Cytomegalovirus, and possibly Epstein-Barr virus,
shedding in breast milk is associated with HIV-1 transmission by
breastfeeding. AIDS. 2015;29:145--53.
9. Gantt S, Carlsson J, Shetty AK, Seidel KD, Qin X, Mutsvangwa
J, et al. Cytomegalovirus and Epstein-Barr virus in breast milk
are associated with HIV-1 shedding but not with mastitis. Aids.
2008;22:1453--60.
0. Daud II, Coleman CB, Smith NA, Ogolla S, Simbiri K, Bukusi EA,
et al. Breast-milk as a potential source of Epstein-Barr virus
transmission among infants living in a malaria endemic region
of Kenya. J Infect Dis. 2015;212:1735--42.
1. Daud II, Ogolla S, Amolo AS, Namuyenga E, Simbiri K, Bukusi
EA, et al. Plasmodium falciparum infection is associated with
Epstein-Barr virus reactivation in pregnant women living in
malaria holoendemic area of Western Kenya. Matern Child
Health J. 2015;19:606--14.
2. Glenn WK, Whitaker NJ, Lawson JS. High risk human papillo-
mavirus and Epstein Barr virus in human breast milk. BMC Res
Notes. 2012;5:477.
3. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The patho-
genesis of Epstein-Barr virus persistent infection. Curr Opin
Virol. 2013;3:227--32.
4. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Identi-
ﬁcation of the site of Epstein-Barr virus persistence in vivo as a
resting B cell. J Virol. 1997;71:4882--91.
5. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S,
et al. Quantitative analysis of Epstein-Barr virus load by using a
real-time PCR assay. J Clin Microbiol. 1999;37:132--6.
6. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder
R, Newton D, et al. Exposure to holoendemic malaria results
in elevated Epstein-Barr virus loads in children. J Infect Dis.
2005;191:1233--8.
7. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, et al. Use
of quantitative competitive PCR to measure Epstein-Barr virus
genome load in the peripheral blood of pediatric transplant
patients with lymphoproliferative disorders. J Clin Microbiol.
1997;35:1612--5.
8. Piriou E, Kimmel R, Chelimo K, Middledorp JM, Sumba PO,
Ploutz-Snyder R, et al. Serological evidence for long-term
Epstein-Barr virus reactivation in children living in a holoen-
demic malaria region of Kenya. J Med Virol. 2009;81:1088--93.
9. Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD,
et al. The effects of acute malaria on Epstein-Barr virus (EBV)
load and EBV-speciﬁc T cell immunity in Gambian children.
J Infect Dis. 2009;199:31--8.
45
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
8
8
82. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, All-
day MJ. Epstein-Barr virus latency in B cells leads to epigenetic6  
0. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R,
Kazura JW.  Exposure to holoendemic malaria results in suppres-
sion of Epstein-Barr virus-speciﬁc T cell immunosurveillance in
Kenyan children. J Infect Dis. 2007;195:799--808.
1. Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist
A, et al. Clearance of circulating Epstein-Barr virus DNA in chil-
dren with acute malaria after antimalaria treatment. J Infect
Dis. 2006;193:971--7.
2. Rasti N, Falk KI, Donati D, Gyan BA, Goka BQ, Troye-Blomberg M,
et al. Circulating Epstein-Barr virus in children living in malaria-
endemic areas. Scand J Immunol. 2005;61:461--5.
3. Yone CL, Kube D, Kremsner PG, Luty AJ. Persistent Epstein-Barr
viral reactivation in young African children with a history of
severe Plasmodium falciparum malaria. Trans R Soc Trop Med
Hyg. 2006;100:669--76.
4. Reynaldi A, Schlub TE, Chelimo K, Sumba PO, Piriou E, Ogolla
S, et al. The impact of malaria co-infections on longitudinal
Epstein-Barr virus kinetics in Kenyan children. J Infect Dis. 2015,
http://dx.doi.org/10.1093/infdis/jiv525
5. Chêne A, Nylén S, Donati D, Bejarano MT, Kironde F, Wahlgren
M, et al. Effect of acute Plasmodium falciparum malaria on
reactivation and shedding of the eight human herpes viruses.
PLoS One. 2011;6:e26266.
6. Chattopadhyay PK, Chelimo K, Embury PB, Mulama DH, Sumba
PO, Gostick E, et al. Holoendemic malaria exposure is asso-
ciated with altered Epstein-Barr virus-speciﬁc CD8(+) T-cell
differentiation. J Virol. 2013;87:1779--88.
7. Snider CJ, Cole SR, Chelimo K, Sumba PO, Macdonald PD, John
CC, et al. Recurrent Plasmodium falciparum malaria infections
in Kenyan children diminish T-cell immunity to Epstein Barr virus
lytic but not latent antigens. PLoS One. 2012;7:e31753.
8. Lam KM, Syed N, Whittle H, Crawford DH. Circulating
Epstein-Barr virus-carrying B cells in acute malaria. Lancet.
1991;337:876--8.
9. Donati D, Zhang LP, Chêne A, Chen Q, Flick K, Nyström M, et al.
Identiﬁcation of a polyclonal B-cell activator in Plasmodium
falciparum.  Infect Immun. 2004;72:5412--8.
0. Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q,
Falk KI, et al. A molecular link between malaria and Epstein-Barr
virus reactivation. PLoS Pathog. 2007;3:e80.
1. Jayasooriya S, Hislop A, Peng Y, Croom-carter D, Jankey Y, Bell
A, et al. Revisiting the effect of acute P. falciparum malaria
on Epstein-Barr virus: host balance in the setting of reduced
malaria endemicity. PLoS One. 2012;7:e31142.
2. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W,  Harmsen
MC, The TH, et al. Frequent monitoring of Epstein-Barr virus
DNA load in unfractionated whole blood is essential for early
detection of posttransplant lymphoproliferative disease in high-
risk patients. Blood. 2001;97:1165--71.
3. Wilmore JR, Asito AS, Wei C, Piriou E, Sumba PO, Sanz I, et al.
AID expression in peripheral blood of children living in a malaria
holoendemic region is associated with changes in B cell subsets
and Epstein-Barr virus. Int J Cancer. 2015;136:1371--80.
4. Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, Thorley-
Lawson DA. A multifactorial role for P. falciparum malaria
in endemic Burkitt’s lymphoma pathogenesis. PLoS Pathog.
2014;10:e1004170.
5. Okazaki IM, Kotani A, Honjo T. Role of AID in tumorigenesis. Adv
Immunol. 2007;94:245--73.6. McBride KM, Gazumyan A, Woo EM, Schwickert TA, Chait BT,
Nussenzweig MC. Regulation of class switch recombination
and somatic mutation by AID phosphorylation. J Exp Med.
2008;205:2585--94.R.  Rochford
7. Ramiro AR, Jankovic M, Callen E, Diﬁlippantonio S, Chen HT,
McBride KM, et al. Role of genomic instability and p53 in AID-
induced c-myc-Igh translocations. Nature. 2006;440:105--9.
8. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett
Y, Diﬁlippantonio S, et al. AID is required for the chromosomal
breaks in c-myc that lead to c-myc/IgH translocations. Cell.
2008;135:1028--38.
9. Kotani A, Kakazu N, Tsuruyama T, Okazaki IM, Muramatsu M,
Kinoshita K, et al. Activation-induced cytidine deaminase (AID)
promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.
Proc Natl Acad Sci U S A. 2007;104:1616--20.
0. Robbiani DF, Deroubaix S, Feldhahn N, Oliveira TY, Callen E,
Wang Q, et al. Plasmodium infection promotes genomic instabil-
ity and AID-dependent B cell lymphoma. Cell. 2015;162:727--37.
1. Agopian J, Navarro JM, Gac AC, Lecluse Y, Briand M, Grenot P,
et al. Agricultural pesticide exposure and the molecular con-
nection to lymphomagenesis. J Exp Med. 2009;206:1473--83.
2. Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R,
Martinez-Maza O. Elevated expression of activation induced
cytidine deaminase in peripheral blood mononuclear cells pre-
cedes AIDS-NHL diagnosis. AIDS. 2007;21:2265--70.
3. Potup P, Kumsiri R, Kano S, Kalambaheti T, Looareesuwan
S, Troye-Blomberg M, et al. Blood stage Plasmodium fal-
ciparum antigens induce immunoglobulin class switching in
human enriched B cell culture. Southeast Asian J Trop Med
Public Health. 2009;40:651--64.
4. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt
lymphoma. J Clin Pathol. 2007;60:1397--402.
5. Gutiérrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas
ML, et al. Molecular epidemiology of Burkitt’s lymphoma from
South America: differences in breakpoint location and Epstein-
Barr virus association from tumors in other world regions. Blood.
1992;79:3261--6.
6. Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb
CE, et al. Burkitt lymphoma in Brazil is characterized by geo-
graphically distinct clinicopathologic features. Am J Clin Pathol.
2008;130:946--56.
7. González Saldan˜a N, Monroy Colín VA, Pin˜a Ruiz G, Juárez Olguín
H. Clinical and laboratory characteristics of infectious mononu-
cleosis by Epstein-Barr virus in Mexican children. BMC Res Notes.
2012;5:361.
8. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al.
Atypical memory B cells are greatly expanded in individuals liv-
ing in a malaria-endemic area. J Immunol. 2009;183:2176--82.
9. Asito AS, Moormann AM, Kiprotich C, Ng’ang’a ZW, Ploutz-
Snyder R, Rochford R. Alterations on peripheral B cell subsets
following an acute uncomplicated clinical malaria infection in
children. Malar J. 2008;7:238.
0. Urban BC, Hien TT, Day NP, Phu NH, Roberts R, Pongponratn
E, et al. Fatal Plasmodium falciparum malaria causes speciﬁc
patterns of splenic architectural disorganization. Infect Immun.
2005;73:1986--94.
1. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin
A, et al. Malaria hemozoin is immunologically inert but rad-
ically enhances innate responses by presenting malaria DNA
to Toll-like receptor 9. Proc Natl Acad Sci U S A. 2007;104:
1919--24.repression and CpG methylation of the tumour suppressor gene
Bim. PLoS Pathog. 2009;5:e1000492.
